NewAmsterdam Pharma Company N.V. (NAMS)
NEUTRAL基本面
33
价格
$27.19
市值
$3.14B
第一部分 · 这家公司值多少
概览
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$7M
最近12个月（截至2026/6/30）
净利润
$-260M
最近12个月（截至2026/6/30）
自由现金流
$-148M
股东权益合计
$683M
负债合计
$86M
流动比率
9.03
利息覆盖率
-
债务/EBITDA
-
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$30.63
当前价格
$27.19
安全边际
+11.2%
公允价值区间
$19.91 - $41.34
估算方法
估值指标
市盈率（P/E）
-
ROE
-29.8%
市净率（P/B）
5.08
P/FCF
-
毛利率
-
ROIC
-30.6%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
-30.6%
WACC
8.0%
ROIC − WACC
-38.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
基本面分析标准
通过（6）
- EPS shows upward trend
- Price CAGR 23.38%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 91% Buy
未通过（11）
- ROIC -30.6%
- P/B Ratio 5.08
- Operating Margin -3432.2%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -38.3%
- Earnings Surprise avg -23.2%
- Share Dilution 25.6%
- Net Margin Trend -3644.2% vs -258.9%
- Piotroski F-Score 3/9
不可用（10）
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-评分
存在严重财务隐患
盈利质量
低质量：需深入审查会计处理
股权稀释
正在发行新股，稀释所有权
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Dr. Michael Harvey Davidson FACC, Facp., M.D. | CEO, President & Executive Director | 69 |
| Dr. Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D. | Founder, Chief Scientific Officer, Member of Executive Board & Director | 71 |
| Mr. Mayur Amrat Somaiya | Chief Financial Officer | 51 |
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有：它帮助你在基本面说服你之后，选择何时买入。包含：技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for NAMS, sourced from Markets Gazette.